Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

World journal of gastroenterology - 28 May 2015

Lim Kieron B L, Sima Hamid R, Fiel M Isabel, Khaitova Viktoriya, Doucette John T, Chernyiak Maria, Ahmad Jawad, Bach Nancy, Chang Charissa, Grewal Priya, Kim-Schluger Leona, Liu Lawrence, Odin Joseph, Perumalswami Ponni, Florman Sander S, Schiano Thomas D

Abstract excerpt

AIM: To describe our experience using a low-accelerating-dose regimen (LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus (HCV) recurrence. METHODS: From 2003, a protocolized LADR strategy was employed to treat liver transplant (LT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with recurrent HCV treated with LADR between 1/2003 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to End Stage Liver Disease
Share to Graft Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Liver Transplantation

Share to New York City

Share to Polyethylene Glycols

Share to Virus Activation

Source

Open in PubMed Open full text

Identifiers

PMID: 26034358
DOI: 10.3748/wjg.v21.i20.6236
PMCID: PMC4445100

Genes

ACR
EPO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.PMID 26034358Read ↗

Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.Semantic proximity Read ↗

Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Semantic proximity Read ↗

Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1.Semantic proximity Read ↗

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.Semantic proximity Read ↗

Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.Semantic proximity Read ↗

Optimizing outcome of recurrent hepatitis C virus genotype 4 after living donor liver transplantation: moving forward by looking back.Semantic proximity Read ↗

Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients.Semantic proximity Read ↗

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.Semantic proximity Read ↗

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.Semantic proximity Read ↗

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.